SUBSCRIBE
SUBSCRIBE
Dan Samorodnitsky

Dan Samorodnitsky

News Editor

Dan Samorodnitsky is the news editor at BioSpace. He has a decade of experience covering biotech, genetics and medicine. Before coming to BioSpace he was an editor at Drug Discovery News and Massive Science, and his writing has appeared in outlets such as Quanta, STAT, GROW and many others. He is based in Minneapolis. You can reach him at dan.samorodnitsky@biospace.com.

Drop of blood from puzzles in hands, as metaphor for donation and fight against cancer caused by leukocyte disease. People donate blood to help sick patients in need of plasma transfusions
Cancer
FDA’s Multiple Myeloma Guidance Highlights Decade of Success
New draft guidance from the FDA on multiple myeloma endpoints reflects the new technology available to assess disease and how patient journeys have changed with better treatments.
January 30, 2026
 · 
4 min read
 · 
Dan Samorodnitsky
Composite photo collage of business people hands hold checkered flags success finish vote competition isolated on painted background.
Rare diseases
REGENXBIO Delay Could Put Denali in Pole Position for Hunter Syndrome Approval
The discovery of a tumor in a patient who received REGENXBIO’s gene therapy for Hurler syndrome prompted the FDA to place a hold on that program along with the company’s Hunter syndrome program, which is awaiting an FDA decision on or before Feb. 8.
January 28, 2026
 · 
2 min read
 · 
Dan Samorodnitsky
Podcast
Roche Makes Obesity Splash, Moderna Cans Vaccine Trials, Sarepta’s New Data, More
Roche’s obesity candidate achieves 22.5% weight loss in Phase II; Moderna pulls the plug on late-stage vaccine trials as Health Secretary Robert F. Kennedy’s anti-vaccine policies and rhetoric continues; and embattled gene therapy maker Sarepta announces new data in Duchenne muscular dystrophy.
January 28, 2026
 · 
1 min read
 · 
Heather McKenzie
The headquarters of Intellia Therapeutics, a brick building with two triangular shapes in its roof
Gene editing
FDA Lifts One of Two Clinical Holds on Intellia’s ATTR Gene Editing Program
After a patient safety signal and then death, the FDA in October 2025 placed holds on two of the company’s CRISPR programs for hereditary transthyretin amyloidosis.
January 27, 2026
 · 
2 min read
 · 
Dan Samorodnitsky
The Westin St. Francis in San Francisco, home of the J.P. Morgan Healthcare Conference.
JPM
JPM26: Biopharma Projected Positivity in San Francisco. Now It’s Time To Execute
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
January 27, 2026
 · 
6 min read
 · 
Annalee Armstrong
Biotechnology and molecular genetic engineering. 3D illustration of science and molecular technology.
Duchenne muscular dystrophy
Sarepta’s DMD Gene Therapy Staves Off Disease Three Years After Treatment
After a spate of patient deaths in 2025 linked to the company’s Duchenne gene therapy, Sarepta shared new data showing benefits of the therapy three years after dosing.
January 26, 2026
 · 
2 min read
 · 
Dan Samorodnitsky
Johnson and Johnson sign
Earnings
J&J Aims for $100B in Sales, Puts Stelara Patent Cliff ‘in the Rearview Mirror’
Reporting Q4 and full year earnings on Wednesday, J&J executives hailed growth across the healthcare giant’s portfolio while standing fast on its talc lawsuit and tariffs.
January 21, 2026
 · 
2 min read
 · 
Dan Samorodnitsky
Industry Leader and Market Dominance of a Company
Business
JPM26: KalVista’s HAE Win Is a ‘Tale of Two Markets’
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
January 21, 2026
 · 
3 min read
 · 
Dan Samorodnitsky
Podcast
JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return
The obesity market and Most Favored Nation drug pricing were among the topics de jour at the J.P. Morgan Healthcare Conference last week, while smaller biotechs sought to assure investors that their regulatory ducks are in a row; Novo Nordisk’s oral obesity pill got off to a hot start while the FDA delayed a decision on Eli Lilly’s investigational offering; and SpyGlass Pharma and AgomAb Therapeutics join the 2026 IPO club.
January 21, 2026
 · 
1 min read
 · 
Heather McKenzie
Vector artwork depicts underdog wins.
Obesity
JPM26: After a Tough 2025, Biohaven Is Gearing Up To Challenge Goliath—Lilly
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
January 20, 2026
 · 
3 min read
 · 
Dan Samorodnitsky
Top view of successful businessman lost in labyrinth
RNA editing
JPM26: Korro Bio Looks To Save Itself Despite Unenviable Position
After a cacophony of troubles hit the RNA editing biotech last fall, CEO Ram Aiyar is in San Francisco to develop partnerships, pitch the potential of its new AATD program and find more money to keep the dream alive.
January 16, 2026
 · 
3 min read
 · 
Dan Samorodnitsky
place marker transportation to the destination, Locating destinations and locations travel for business in large places,3d rendering
Editorial
JPM26: Verizon Outage Unites Directionless Conference Goers
It doesn’t matter how many times you have traversed Union Square; no one knows which way is north, or where The Westin is in relation to the Ritz Carlton. A Verizon outage brought that into focus on Wednesday of JPM week.
January 15, 2026
 · 
1 min read
 · 
Annalee Armstrong
Nov 2, 2019 San Francisco / CA / USA - People visiting the Gilead exhibition at the Bay Area Science festival; free access, no ticket required
HIV
JPM26: Gilead Captures Sunny JPM Mood With Yeztugo Numbers, HIV Vibes
At a J.P. Morgan media event Tuesday, the Gilead C-suite seemed to be walking on air as they highlighted Yeztugo’s capture of the HIV market and its plans for business development.
January 14, 2026
 · 
3 min read
 · 
Dan Samorodnitsky
Podcast
Deals Roll at JPM26, Policy Front and Center, IPOs Are Back, FDA Stays Busy
AbbVie and Novartis strike billion-dollar pacts while attendees at the J.P. Morgan Healthcare Conference await that one big M&A deal and Merck teases limitless buying capacity; Eli Lilly readies for potential orforglipron launch while Novo Nordisk laments compounders; the IPO window cracks open; and the FDA concludes that GLP-1s do not pose a suicide risk.
January 14, 2026
 · 
2 min read
 · 
Heather McKenzie
abstract image of DNA, tablets and planet earth. 3D-image
Policy
At JPM26, Experts Try To Look Past the Most Favored Nation ‘Distraction’
Former European Trade Commissioner Phil Hogan and former U.S. Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
January 12, 2026
 · 
4 min read
 · 
Dan Samorodnitsky
Load More